Thrombophilia

• 

  Subject Areas on Research

  • A clinical cardiology perspective of thrombophilias. 
  • Adverse effects of corticosteroids on the cardiovascular system. 
  • Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. 
  • Anticoagulants in pregnancy. 
  • Antiplatelet therapy in pediatric cardiovascular patients. 
  • Atherothrombotic disorders: new insights from hematology. 
  • COVID-19: Thrombosis, thromboinflammation, and anticoagulation considerations. 
  • Characteristics of abdominal vein thrombosis in children and adults. 
  • Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies. 
  • Characterization of the hypercoagulable state in patients with sickle cell disease. 
  • Clinical and laboratory evaluation of thrombophilia. 
  • Clinical causes and treatment of the thrombotic storm. 
  • Coagulation abnormalities in patients with hip osteonecrosis. 
  • Coagulation and fibrinolytic protein kinetics in cardiopulmonary bypass. 
  • Coagulation disorders and their cutaneous presentations: Pathophysiology. 
  • Coagulopathy of Coronavirus Disease 2019. 
  • Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies in patients with deep vein thrombosis. 
  • Cutaneous collagenous vasculopathy in a middle-aged woman with a history of prothrombin G20210A thrombophilia. 
  • Depression and cardiovascular disease: mechanisms of interaction. 
  • Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. 
  • Diagnostic and Therapeutic Challenges. 
  • Do East Asians have different hypercoagulable states compared with Western population? 
  • Does Anticoagulation Improve Flap Outcomes in Hypercoagulable Patients? A Systematic Review. 
  • Dysregulation of hemostasis by cancer. 
  • Effects of inherited thrombophilic mutations in an adolescent with antiphospholipid syndrome and systemic lupus erythematosus. 
  • Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk. 
  • Endothelial cell function and endothelial-related disorders following haematopoietic cell transplantation. 
  • Etiology and assessment of hypercoagulability with lessons from heparin-induced thrombocytopenia. 
  • Evidence-Based Practical Guidance for the Antithrombotic Management in Patients With Coronavirus Disease (COVID-19) in 2020. 
  • Excess factor VIII and hypercoagulability. 
  • Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation. 
  • High altitude: a hypercoagulable state: results of a prospective cohort study. 
  • Hypercoagulability - The Underdiagnosed and Undertreated Nemesis of Congenital Heart Surgery. 
  • Hypercoagulability affecting early vein graft patency does not exist after off-pump coronary artery bypass. 
  • Hypercoagulability and coronavirus disease 2019-associated hypoxemic respiratory failure: Mechanisms and emerging management paradigms. 
  • Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic RIsk Progression (TRIP) study. 
  • Hypercoagulable states in cardiovascular disease. 
  • Hypercoagulable states: a review. 
  • Hypercoagulation and thrombophilia in liver disease. 
  • Infant cardiopulmonary bypass: a procoagulant state. 
  • Inherited thrombophilia in childhood arterial stroke: data from Lebanon. 
  • Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. 
  • Microparticles from stored red blood cells promote a hypercoagulable state in a murine model of transfusion. 
  • On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF. 
  • Pathophysiological Response to Trauma-Induced Coagulopathy: A Comprehensive Review. 
  • Perioperative Management of the Gynecologic Patient on Long-term Anticoagulation. 
  • Personalizing Antithrombotic Therapy in COVID-19: Role of Thromboelastography and Thromboelastometry. 
  • Physiologic and biochemical rationale for treating COVID-19 patients with hyperbaric oxygen. 
  • Potential thrombophilic mutations/polymorphisms in patients with no flow-limiting stenosis after myocardial infarction. 
  • Pregnancy-associated thrombosis. 
  • Prenatal screening for thrombophilia: the background and the approach. 
  • Prevention and treatment of venous thromboembolism in pregnancy. 
  • Prevention of venous thromboembolism in pregnancy: a review of guidelines, 2000-2011. 
  • Regulatable aptamers in medicine: focus on antithrombotic strategies. 
  • Role of thrombotic and fibrinolytic alterations in the pathogenesis and treatment of osteonecrosis. 
  • SARS-CoV-2 and Stroke in a New York Healthcare System. 
  • Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. 
  • Screening for hypercoagulable syndromes following stroke. 
  • Sickle cell disease is associated with iron mediated hypercoagulability. 
  • Suppression of Fibrinolysis and Hypercoagulability, Severity of Hypoxemia, and Mortality in COVID-19 Patients: A Retrospective Cohort Study. 
  • Temporal trends in maternal medical conditions and stillbirth. 
  • The U.S. Thrombosis and Hemostasis Centers pilot sites program. 
  • The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event. 
  • The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. 
  • The scientific basis for evaluation and management of thrombotic disorders. 
  • The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibitors (SYNERGY) trial. 
  • Thromboembolism in pregnancy: recurrence risks, prevention and management. 
  • Thrombogenicity markers for early diagnosis and prognosis in COVID-19: a change from the current paradigm? 
  • Thromboinflammation and the hypercoagulability of COVID-19. 
  • Thrombophilia screening in asymptomatic children. 
  • Thrombophilias and recurrent miscarriage. 
  • Thrombophilias: when should we test and how does it help? 
  • Thrombosis during pregnancy and the postpartum period. 
  • Thrombosis, thrombophilia, and thromboprophylaxis in pregnancy. 
  • Thrombotic preparedness in aging: a translatable construct for thrombophilias? 
  • Thrombotic storm revisited: preliminary diagnostic criteria suggested by the thrombotic storm study group. 
  • Tissue factor and fibrin in tumor angiogenesis. 
  • Why is depression bad for the failing heart? A review of the mechanistic relationship between depression and heart failure. 
  • [Hematologic diseases: from within the heart]. 
  • [Recent advances in atherothrombotic diseases]. 
• 

  Keywords of People

  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Schanberg, Laura Eve, Professor of Pediatrics, Pediatrics, Rheumatology
  • Shah, Nirmish Ramesh, Associate Professor of Medicine, Medicine, Hematology